Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 5, 2013, Pages 427-432

  Irons, Brian K ^a   Trujillo, Alex ^b   Seifert, Charles F ^a   Simoni, Jan S ^b   Doctolero, Susan ^a   Abo Salem, Elsayed ^b   Meyerrose, Gary E ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

aliskiren; amlodipine; atherosclerosis; biomarkers; C reactive protein; nitric oxide

Indexed keywords

8 ISOPROSTANE; ALISKIREN; AMLODIPINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MALAISE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ALISKIREN; AMLODIPINE; ATHEROSCLEROSIS; BIOMARKERS; C-REACTIVE PROTEIN; NITRIC OXIDE;

AGED; AMIDES; AMLODIPINE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN;

EID: 84882289794     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413489772     Document Type: Article

References (43)

1. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol. 2006 ; 47 (10). 2130-2139
2. Smith S, Benjamin E, Bonow R, et al. AHA/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 ; 124 (22). 2458-2473
3. Tsikouris J, Cox C.. Pharmacologic blockade of the renin-angiotensin system: Vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy. 2003 ; 23 (9). 1141-1152
4. Ding H, Triggle C.. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: Assessing the health of the endothelium. Vasc Health Risk Manag. 2005 ; 1 (1). 55-71
5. Rask-Madsen C, King G. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007 ; 3 (1). 46-56
6. Mita T, Watada H, Uchino H, et al. Association of C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-state type 2 diabetes mellitus. Endocrine J. 2006 ; 53 (5). 693-698
7. Nickenig G, Ostergren J, Struiijker-Boudier H. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin Angiotesin Aldosterone Syst. 2006 ; 7 (suppl 1). S1 - S7
8. Van Tassell B, Munger M. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother. 2007 ; 41 (3). 456-464
9. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007 ; 49 (2). 276-284
10. Simoni J, Simoni G, Griswold JA, et al. Role of free hemoglobin in 8-iso prostaglandin F2-alpha synthesis in chronic renal failure and its impact on CD163-Hb scavenger receptor and on coronary artery endothelium. ASAIO J. 2006 ; 52 (6). 652-661
11. Simoni J, Simoni G, Garcia EL, et al. Protective effect of selenium on hemoglobin mediated lipid peroxidation in vivo. Artif Cells Blood Substit Immobil Biotechnol. 1995 ; 23 (4). 469-486
12. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002 ; 25 (1). 95-100
13. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15). 1547-1559
14. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin II type I receptor antagonist. Circulation. 2004 ; 109 (21). 2492-2499
15. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 ; 39 (1). E1 - E8
16. Moutzouri E, Florentin M, Elisaf M, Mikhailidis D, Liberopoulos E.. Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension. Curr Vasc Pharmacol. 2010 ; 8 (3). 344-362
17. Lu H, Rateri DL, Feldman DL, Jr RJ, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008 ; 118 (3). 984-993
18. Kühnast S, van der Hoorn JW, van den Hoek AM, et al. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J Hypertens. 2012 ; 30 (1). 107-116
19. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011 ; 34 (3). 308-313
20. Mervaala EM, Müller DN, Park JK, et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999 ; 33 (1 pt 2). 389-395
21. Ogawa S, Nako K, Okamura M, Senda M, Mori T, Ito S. Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertens Res. 2011 ; 34 (3). 400-401
22. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 ; 370 (9583). 221-229
23. Ishibashi K, Kurisu S, Kato Y, et al. Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker. Heart Vessels. 2013 ; 28 (1). 7-11
24. Solomon S, Shin S, Shah A, et al. Effect of direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infraction with systolic dysfunction. Eur Heart J. 2011 ; 32 (10). 1227-1234
25. Solomon S, Appelbaum E, Manning W, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 ; 119 (4). 530-537
26. McMurray J, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 ; 1 (1). 17-24
27. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009 ; 32 (10). 1873-1879
28. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 ; 358 (23). 2433-2446
29. Parving H, Brenner B, McMurray J, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 ; 367 (23). 2204-2213
30. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987 ; 2 (8549). 3-9
31. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med. 2000 ; 28 (12). 1745-1750
32. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001 ; 103 (9). 1194-1197
33. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997 ; 96 (12). 4219-4225
34. Tsihlis ND, Oustwani CS, Vavra AK, Jiang Q, Keefer LK, Kibbe MR. Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell Biochem Biophys. 2011 ; 60 (1-2). 89-97
35. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm KA. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation. 2004 ; 109 (12). 1536-1542
36. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002 ; 105 (4). 457-461
37. Clarkson P, Mullen MJ, Donald AE, et al. The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. Atherosclerosis. 2001 ; 154 (1). 171-177
38. Vinh A, Widdop RE, Drummond GR, Gaspari TA. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008 ; 77 (1). 178-187
39. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010 ; 30 (8). 1606-1613
40. Saris JJ, 't Hoen PA, Garrelds IM, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension. 2006 ; 48 (4). 564-571
41. Schefe JH, Neumann C, Goebel M, et al. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed byaliskiren. J Hypertens. 2008 ; 26 (9). 1787-1794
42. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008 ; 52 (1). 130-136
43. Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension. 2008 ; 51 (3). 682-688